What is the Impact Factor of Neuropharmacology?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Neuropharmacology is 4.70, ranking in quartile Q1 of Web of Science (SCIE).

Is Neuropharmacology indexed in Web of Science or Scopus?

Yes, Neuropharmacology is indexed in Web of Science (SCIE, Q1 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 1.568 (Q1) and an H-index of 206.

Who publishes Neuropharmacology and what is the Article Processing Charge (APC)?

Neuropharmacology is published by Elsevier Ltd. The estimated Article Processing Charge (APC) is approximately $3,568 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Neuropharmacology?

The official ISO-4 abbreviation of Neuropharmacology is "NEUROPHARMACOLOGY" with common acronym "neuropharm". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q1Scopus Q1SCImago #2,239Hybrid

Neuropharmacology

Acronym:neuropharm

•

Abbreviation (ISO):NEUROPHARMACOLOGY

•

Identifier (ISSN):0028-3908(Print)/1873-7064(Online)

•

Publisher:Elsevier Ltd

Official Website Submission Portal Compare

Clarivate IF (2026)

4.7↑ +0.1

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Neuropharmacology

WoS Q1

Annual Impact Factor Metric

Current (2026):4.7

Scopus SJR & RankScopus Q1

1.568

#2,239

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

206

206 papers with at least that number of citations each

WoS: SCIE / JCRQ1

Self-Citation Rate4.3%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

357articles/year

30.46% Gold OA•99.22% Original Research

Aims & Scope

Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).

Topics Covered (Recognized by AI)

Medicine95.6%Biology95.5%Internal medicine91.7%Chemistry89.2%Psychology85.7%Biochemistry85.4%Genetics83.3%Neuroscience79.4%Endocrinology75%Receptor74.2%Pharmacology60.1%Psychiatry44%Agonist28.8%Antagonist26.2%Anesthesia25.7%Organic chemistry24.7%Dopamine24%Cell biology21.3%Physics21.1%

Primary Research Areas

Medicine Neuroscience

Official Website NLM PubMed Catalog Submission Portal SCImago Profile 2 Calls for Papers

2 calls

Special Issues

Calls for Papers

2 Calls for Papers · Automatically synced from ScienceDirect & publishers

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

NEUROSCIENCES

Rank77/330

IndexSCIE

JCRSCIE2026

PHARMACOLOGY & PHARMACY

Rank78/356

IndexSCIE

JCISCIE2026

NEUROSCIENCES

Rank49/330

IndexSCIE

JCISCIE2026

PHARMACOLOGY & PHARMACY

Rank47/356

IndexSCIE

Category	Index	Rank	Quartile
NEUROSCIENCES	JCRSCIE	77/330	Q1
PHARMACOLOGY & PHARMACY	JCRSCIE	78/356	Q1
NEUROSCIENCES	JCISCIE	49/330	Q1
PHARMACOLOGY & PHARMACY	JCISCIE	47/356	Q1

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF4.7

Articles / Year269

Total Citations93

2025

IF4.6

Articles / Year396

Total Citations1,319

2024

IF4.6

Articles / Year306

Total Citations2,526

2023

IF4.7

Articles / Year255

Total Citations3,683

2022

IF5.273

Articles / Year281

Total Citations5,957

Year	Impact Factor	Articles / Year	Total Citations
2026	4.7	269	93
2025	4.6	396	1,319
2024	4.6	306	2,526
2023	4.7	255	3,683
2022	5.273	281	5,957
2021	5.25	359	9,298
2020	4.431	376	11,279
2019	4.367	408	14,187
2018	4.249	480	18,085
2017	—	481	23,530
2016	—	444	19,349
2015	—	443	21,613

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #2,239Scopus Q1SCImago Profile

Scopus Coverage:1962-2026

•

Scopus Broad Areas:NeurosciencePharmacology, Toxicology and Pharmaceutics

Scopus Citation Rank (SJR)Q1

1.568

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1

Citations / Doc (2 years)

5.27

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,568 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations3,954

3-Year Documents749

Citable Documents733

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate46.1%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Cellular and Molecular NeuroscienceQ1

PharmacologyQ1

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 4.3%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

2区 (Zone 2)Medicine

Minor Category (Specific Field):

2区NEUROSCIENCES

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Neuropharmacology (acronym: neuropharm, abbr: NEUROPHARMACOLOGY, ISSN: 0028-3908) is a peer-reviewed international scholarly journal in the field of Medicine, published by Elsevier Ltd in England since 1970. The periodical holds a Journal Impact Factor (JIF) of 4.70, ranking in quartile Q1 of Web of Science (SCIE), a Scopus SJR indicator of 1.568 (Q1), an H-index of 206.

The journal enforces rigorous peer evaluation with a publication frequency of Semimonthly, an annual output of approximately 357 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,568 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.